Capecitabine trials for HER2-positive Breast Cancer

All Capecitabine trials · All HER2-positive Breast Cancer trials

Phase breakdown

Recruiting trials studying Capecitabine for HER2-positive Breast Cancer

• A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
  NCT06992882 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
  NCT06016387 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Capecitabine for HER2-positive Breast Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.